KHC — The Kraft Heinz Company

Sentiment is cautious because Q2 2026 organic sales fell 1.3%, adjusted EPS dropped 18.8% to $0.56, and the $6.4B operating loss from non-cash impairments reminded investors of weak returns on past deals. Analyst positioning is defensive: 20 of 35 ratings are Hold, 11 are Sell, only 4 are Buy, and the consensus price target of $22.75 sits below the $24.60 price. The 6.44% yield and $1.66B H1 2026 free cash flow prevent outright panic, but price below the 20-day and 50-day SMAs shows the market is waiting for proof that the $700M reinvestment plan is stabilizing volumes.

Revenue has been flat-to-down over the three-year window: quarterly sales went from $6.57B in Q3 2023 to $6.26B in Q2 2026, with recent YoY declines of -1.4% in Q2 2026, -2.3% in Q3 2025, and -3.4% in Q4 2025. Gross margin compressed to 32.4% in Q2 2026 from 34.4% a year earlier and 35.4% two years earlier, while adjusted EPS fell 18.8% YoY. GAAP operating and net income are distorted by huge non-cash impairments (-$6.43B operating loss in Q2 2026, -$7.97B in Q2 2025), but free cash flow remains solid at $893M in Q2 2026 and $1.66B in H1 2026. This looks like slow structural erosion in volumes and margins, not a one-quarter blip.

As of 2026-09-13, trailing P/E is negative (-8.6) and PEG is meaningless because of impairments, so forward valuation is the right lens: the $24.60 price divided by next-FY consensus EPS of $2.053 gives roughly 12.0x forward earnings. That is cheap versus its own 5-year average P/E of 23.2x, though that average was set on higher normalized earnings. P/B of 0.81 and P/S of 1.17 versus a 5-year average P/S of 1.57 also show a deep discount, and the 6.44% dividend yield is high. The stock is cheap, but the multiple reflects real concerns: negative organic growth, 32.8% gross margin, negative TTM operating margin, and $17.6B of long-term debt.

The market is pricing a no-growth, high-payout future at roughly 12x forward EPS despite a 6.4% yield. If Q3 2026 shows North American volumes stabilizing and the $700M reinvestment plan starts lifting organic sales, EPS estimates could edge up and the multiple could re-rate toward 13-14x, implying $26.70-$28.74. If volume declines persist, 12x is not a floor; estimates could fall below $2.00 and force another leg down. Watch the gap between adjusted EPS (still beating lowered bars) and GAAP losses from impairments - the market is looking past impairments for now, but repeated write-downs erode credibility.

As of 2026-09-13, RSI(14) was 43.49, neutral rather than oversold. The $24.60 price sat 2.59% below the 20-day SMA, 3.41% below the 50-day SMA, but 2.41% above the 200-day SMA. It is a mildly weak, range-bound tape inside the 52-week range of $21.04-$28.09; the 6-month return was +8.95%, but the 1-week return was -1.01%. Entry-timing implication: there is no urgent buy signal, so waiting for either a reclaim of the 50-day SMA or an RSI push below 30 would offer a better risk/reward before treating the yield as an entry point.

• Consumer price sensitivity after cumulative inflation: shoppers are trading down or moving to private label, pressuring KHC volumes in North America.
• Input-cost inflation projected at 4%-5% for 2027, which management plans to absorb through productivity rather than broad price hikes - a margin risk if productivity falls short.
• Higher-for-longer interest rates pressure heavily levered staples; KHC's $17.6B long-term debt and refinancing needs make it rate-sensitive, though it repaid $1.9B post-Q2.
• Defensive sector rotation: if growth slows, staples may attract flows, but KHC's weak organic growth makes it a laggard within the group.
• FX and emerging-market volatility affect the International Developed and Emerging Markets segments, though North America remains the key profit pool.

• Q3 2026 earnings in late October or early November 2026: the first real test of whether incremental marketing, sales, and R&D spending is stabilizing volumes.
• Investor Day on 2026-11-12: management will outline multi-year strategic targets, details on the $700M turnaround/reinvestment plan, and long-term capital allocation plans.
• Debt reduction and refinancing progress: $1.9B paid down post-Q2; further deleveraging could ease balance-sheet concerns.
• Disney alliance and co-branded product launches such as the Jell-O/Tower 28 collaboration - potentially incremental sales and marketing relevance, though likely small near-term.
• NYSE listing transfer: not fundamental, but it could marginally broaden the investor base and improve liquidity.

• Persistent North American volume erosion: Q2 2026 organic sales fell 1.3%, with price-sensitive consumers and private-label competition taking share.
• Margin compression from reinvestment and input costs: gross margin fell to 32.4% in Q2 2026, and the $700M plan could pressure near-term profits.
• Impairment/goodwill risk: the Q2 2026 $6.4B non-cash operating loss reduced stockholders' equity to $36.0B; further write-downs would signal more past M&A value destruction.
• High leverage: $17.6B long-term debt and $36.0B equity; rising rates or a decline in free cash flow could threaten dividend coverage.
• Execution risk on the turnaround: management's plan may not reverse market-share losses, and analyst consensus is already cautious with 20 Hold, 11 Sell, and only 4 Buy ratings.

KHC is a classic cheap-but-challenged staple: about 12x forward EPS, 0.81x book value, a 6.44% yield, and solid free cash flow offer a margin of safety, but negative organic growth, margin compression, and a large impairment show the core brands are losing ground. It is not a compelling buy until Q3 results and the November Investor Day prove the reinvestment plan is stabilizing volumes; income investors may collect the yield, but total return is likely capped near term.

Applied 12.5x to next-FY consensus EPS of $2.053 - a discount to staples peers and KHC's own 5-year average P/E of 23.2x because organic growth is negative, leverage is high, and ROIC is weak - yielding $25.66; cross-checked with 1.25x forward sales of $24.66B, which implies about $26.00 and corroborates a mid-$25s fair value.